Drugs / NY-ESO-1 peptide vaccine
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01673217 | Apr 2009 → Oct 2011 | fallopian tube cancer, malignant epithelial tumor of ovary, primary peritoneal carcinoma | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT00037037 | Oct 2001 → ? | cutaneous melanoma | Herbert Irving Comprehensive Cancer Center | Unknown | No outcome recorded |
| Phase 1 | NCT00027911 | Apr 2001 → Jun 2005 | sarcoma | Columbia University | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00079144 | Jan 2004 → Aug 2005 | cutaneous melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00020397 | Nov 2000 → Jul 2005 | cutaneous melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00066729 Background | Jun 2003 → May 2006 | fallopian tube cancer, ovarian cancer, peritoneum cancer | Ludwig Institute for Cancer Research | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NY-ESO-1 peptide vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01673217 ↗ |
| Modality | Vaccine | “NY-ESO-1 peptide vaccine” NCT00020397 ↗ |
| Route | Subcutaneous | “Patients receive NY-ESO-1b peptide vaccine emulsified with Montanide® ISA-51 subcutaneously” NCT00066729 ↗ |